Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein.
COVID-19
SARS-CoV-2
adenovirus
infectious diseases
recombinant DNA vaccines
Journal
Antibody therapeutics
ISSN: 2516-4236
Titre abrégé: Antib Ther
Pays: United States
ID NLM: 101730822
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
24
05
2022
revised:
27
06
2022
accepted:
04
07
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Additional COVID-19 vaccines that are safe and immunogenic are needed for global vaccine equity. Here, we developed a recombinant type 5 adenovirus vector encoding for the SARS-CoV-2 S1 subunit antigen and nucleocapsid as a fusion protein (Ad5.SARS-CoV-2-S1N). A single subcutaneous immunization with Ad5.SARS-CoV-2-S1N induced a similar humoral response, along with a significantly higher S1-specific cellular response, as a recombinant type 5 adenovirus vector encoding for S1 alone (Ad5.SARS-CoV-2-S1). Immunogenicity was improved by homologous prime-boost vaccination, and further improved through intramuscular heterologous prime-boost vaccination using subunit recombinant S1 protein. Priming with low dose (1 × 10
Identifiants
pubmed: 35967905
doi: 10.1093/abt/tbac015
pii: tbac015
pmc: PMC9372896
doi:
Types de publication
Journal Article
Langues
eng
Pagination
177-191Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK130897
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Références
Vaccine. 2005 Jan 11;23(8):1029-36
pubmed: 15620476
Nat Med. 2014 Oct;20(10):1126-9
pubmed: 25194571
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583766
Front Immunol. 2020 Nov 30;11:611337
pubmed: 33329607
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Exp Med. 2020 Nov 2;217(11):
pubmed: 33064151
Procedia Vaccinol. 2011;5:127-136
pubmed: 32288915
Vaccine. 2014 Oct 14;32(45):5975-82
pubmed: 25192975
Adv Drug Deliv Rev. 2021 Apr;171:164-186
pubmed: 33539853
Sci Total Environ. 2020 Aug 1;728:138882
pubmed: 32335410
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Biologicals. 2014 Sep;42(5):237-59
pubmed: 24996452
J Clin Microbiol. 2020 Apr 23;58(5):
pubmed: 32161092
Curr Med Res Pract. 2020 Mar-Apr;10(2):78-79
pubmed: 32292804
Biochemistry. 2009 Dec 22;48(50):11834-6
pubmed: 19928925
EBioMedicine. 2020 May;55:102743
pubmed: 32249203
Antiviral Res. 2020 Jun;178:104792
pubmed: 32272173
J Investig Med. 2022 Jan;70(1):61-67
pubmed: 34611034
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
mBio. 2020 Sep 18;11(5):
pubmed: 32948688
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
NPJ Vaccines. 2021 Aug 5;6(1):97
pubmed: 34354082
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3041-6
pubmed: 23386724
Cell Mol Immunol. 2021 Oct;18(10):2325-2333
pubmed: 34413488
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
J Travel Med. 2022 May 31;29(3):
pubmed: 34918097
BMJ. 2021 Sep 23;374:n2353
pubmed: 34556471
J Control Release. 2020 Jan 10;317:336-346
pubmed: 31756393
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
ChemMedChem. 2013 Mar;8(3):360-76
pubmed: 23316023
Vaccine. 2016 Jan 20;34(4):413-423
pubmed: 26691569
J Virol. 2007 Jun;81(12):6594-604
pubmed: 17428852
Biochem Biophys Res Commun. 2021 Jan 29;538:187-191
pubmed: 33187644
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Clin Infect Dis. 2021 Dec 16;73(12):2257-2264
pubmed: 33515252
Lancet Infect Dis. 2021 Sep;21(9):1212-1213
pubmed: 34332707
Front Microbiol. 2020 Jul 14;11:1526
pubmed: 32760367
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Virol J. 2019 May 27;16(1):69
pubmed: 31133031
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
J Virol. 1997 Mar;71(3):1842-9
pubmed: 9032314
Nat Med. 2021 Nov;27(11):2002-2011
pubmed: 34594036
Immunity. 2021 May 11;54(5):1055-1065.e5
pubmed: 33945786
Nat Rev Genet. 2021 Dec;22(12):757-773
pubmed: 34535792
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
Ann Intern Med. 2021 Aug;174(8):1073-1080
pubmed: 34000201
Vaccines (Basel). 2021 Sep 20;9(9):
pubmed: 34579284
J Immunol. 2021 Mar 1;206(5):931-935
pubmed: 33441437
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Front Immunol. 2021 Mar 08;12:612747
pubmed: 33763063
MedComm (2020). 2021 Dec 16;2(4):838-845
pubmed: 34957469
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
Eur J Immunol. 2021 Jul;51(7):1774-1784
pubmed: 33772778
Nat Med. 2021 Nov;27(11):2025-2031
pubmed: 34526698
J Leukoc Biol. 2005 Jul;78(1):114-21
pubmed: 15845645
Vaccine. 2003 Jan 30;21(7-8):596-600
pubmed: 12531324
J Virol. 2021 Feb 24;95(6):
pubmed: 33443088
Biotechnol Adv. 2009 May-Jun;27(3):297-306
pubmed: 19500547
Lancet. 2021 May 29;397(10289):2043-2046
pubmed: 33991480
Front Immunol. 2020 Oct 28;11:587615
pubmed: 33193414
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
NPJ Vaccines. 2020 Sep 28;5:91
pubmed: 33083026
EBioMedicine. 2016 Nov;13:315-320
pubmed: 27717627
Viruses. 2021 Jun 10;13(6):
pubmed: 34200602
Eur J Immunol. 2019 Oct;49(10):1457-1973
pubmed: 31633216
Viruses. 2020 Jan 29;12(2):
pubmed: 32013152
Lancet. 2003 Dec 6;362(9399):1895-6
pubmed: 14667748
Vaccine. 2017 Aug 16;35(35 Pt A):4461-4464
pubmed: 28576573
J Glob Health. 2021 Jul 03;11:03086
pubmed: 34221356
Nat Med. 2021 Nov;27(11):1874-1875
pubmed: 34764485
Hum Vaccin Immunother. 2014;10(10):2875-84
pubmed: 25483662
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Nat Immunol. 2010 Jun;11(6):535-42
pubmed: 20453843
Biotechnol Prog. 2004 Mar-Apr;20(2):443-8
pubmed: 15058988
Immunity. 2016 Jan 19;44(1):116-130
pubmed: 26795247
Mol Biotechnol. 2005 Mar;29(3):255-72
pubmed: 15767703
Science. 2003 May 30;300(5624):1399-404
pubmed: 12730501
mBio. 2021 Jan 19;12(1):
pubmed: 33468695